,[3], [4], [5], [6],8 Notably, a recent Asia-Pacific consensus paper advised that PIVKA-II in combination with AFP (and USG) shows potential benefit for HCC detection especially in those with small and AFP-negative tumors, which are predominantly early-stage disease.[9], [10], [11]. The gene discussed is AFP; the disease is hepatocellular carcinoma.